Ignacio Matos
Overview
Explore the profile of Ignacio Matos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
765
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aliseda D, Arredondo J, Sanchez-Justicia C, Alvarellos A, Rodriguez J, Matos I, et al.
Br J Surg
. 2024 Feb;
111(2).
PMID: 38381934
Background: Neoadjuvant chemotherapy is increasingly used to treat locally advanced (T3-4 Nx-2 M0) colon cancer due to its potential advantages over the standard approach of upfront surgery. The primary objective...
2.
Galvez-Cancino F, Simpson A, Costoya C, Matos I, Qian D, Peggs K, et al.
Nat Rev Cancer
. 2023 Dec;
24(1):51-71.
PMID: 38062252
The discovery of both cytotoxic T lymphocyte-associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) as negative regulators of antitumour immunity led to the development of numerous immunomodulatory...
3.
Luri-Rey C, Eguren-Santamaria I, Matos I, Berraondo P, Melero I
Clin Cancer Res
. 2023 Sep;
29(21):4320-4322.
PMID: 37656058
Bispecific T-cell engagers and chimeric antigen receptor T cells share the problem of eliciting acute systemic inflammation episodes known as cytokine release syndrome. Knowledge on the sequential waves of cytokines...
4.
Li L, Cappuzzo F, Matos I, Socinski M, Hopkins A, Sorich M
Oncologist
. 2023 Mar;
28(4):e205-e211.
PMID: 36905578
Background: Monotherapy immune checkpoint inhibitor (ICI) used in second- or later-line settings has been reported to induce hyperprogression. This study evaluated hyperprogression risk with ICI (atezolizumab) in the first-, second-,...
5.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, et al.
Clin Cancer Res
. 2023 Feb;
29(12):2250-2265.
PMID: 36749875
Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated...
6.
Yofe I, Landsberger T, Yalin A, Solomon I, Costoya C, Demane D, et al.
Nat Cancer
. 2022 Nov;
3(11):1404.
PMID: 36376510
No abstract available.
7.
Yofe I, Landsberger T, Yalin A, Solomon I, Costoya C, Demane D, et al.
Nat Cancer
. 2022 Oct;
3(11):1336-1350.
PMID: 36302895
Despite the clinical success of checkpoint inhibitors, a substantial gap still exists in our understanding of their mechanism of action. While antibodies to cytotoxic T lymphocyte-associated protein-4 (CTLA-4) were developed...
8.
Matos I, Villacampa G, Hierro C, Martin-Liberal J, Berche R, Pedrola A, et al.
Eur J Cancer
. 2021 Aug;
155:168-178.
PMID: 34385069
Purpose: Patient selection in phase 1 clinical trials (Ph1t) continues to be a challenge. The aim of this study was to develop a user-friendly prognostic calculator for predicting overall survival...
9.
Subbiah V, Hu M, Wirth L, Schuler M, Mansfield A, Curigliano G, et al.
Lancet Diabetes Endocrinol
. 2021 Jun;
9(8):491-501.
PMID: 34118198
Background: Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, selective RET inhibitor, in...
10.
Capdevila J, Fazio N, Lopez C, Teule A, Valle J, Tafuto S, et al.
J Clin Oncol
. 2021 May;
39(20):2304-2312.
PMID: 33945297
Purpose: Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression to targeted agents (TAs). We investigated...